Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimura + Anti-VEGF in IPCV
NCT02397954Phase 2Completed
- Sponsor
- IVERIC bio
- Start
- Mar 2015
- Primary completion
- Oct 2015
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avacincaptad pegol in polypoidal choroidal vasculopathy (PCV), sponsored by IVERIC bio. Primary endpoints: Number of Participants With >15 ETDRS Letter Loss at Month 3, Number of Participants With Ophthalmic Adverse Events at 3 months and 1 more. Started Mar 2015; status: completed.
02
Drugs
avacincaptad pegol
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT02397954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02397954.